OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis $0.32 0.00 (-0.34%) (As of 05:39 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Northwest Biotherapeutics alerts: Email Address About Northwest Biotherapeutics Stock (OTCMKTS:NWBO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NWBO alerts:Sign Up Key Stats Today's Range$0.32▼$0.3350-Day Range$0.30▼$0.4052-Week Range$0.29▼$1.09Volume842,206 shsAverage Volume1.92 million shsMarket Capitalization$392.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Read More… “Buffett Indicator” Predicts 62% Stock Market Crash (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Northwest Biotherapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 0th PercentileNorthwest Biotherapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Northwest Biotherapeutics.Read more about Northwest Biotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Northwest Biotherapeutics is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Northwest Biotherapeutics is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.10% of the outstanding shares of Northwest Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverNorthwest Biotherapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Northwest Biotherapeutics has recently increased by 0.33%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNorthwest Biotherapeutics does not currently pay a dividend.Dividend GrowthNorthwest Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.10% of the outstanding shares of Northwest Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverNorthwest Biotherapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Northwest Biotherapeutics has recently increased by 0.33%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Northwest Biotherapeutics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for NWBO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Northwest Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of Northwest Biotherapeutics is held by insiders.Percentage Held by InstitutionsOnly 0.04% of the stock of Northwest Biotherapeutics is held by institutions.Read more about Northwest Biotherapeutics' insider trading history. Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NWBO Stock News HeadlinesNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below 200-Day Moving Average of $0.43September 20 at 3:37 AM | americanbankingnews.com0K95.IL,0P0000AFQ5,0 (0K95.IL)September 14, 2024 | nz.finance.yahoo.comThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.September 20, 2024 | Investors Alley (Ad)Northwest Biotherapeutics addresses rumors and market activityAugust 4, 2024 | uk.investing.comNorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth OpportunitiesJuly 3, 2024 | prnewswire.comNorthwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual PropertyJune 17, 2024 | prnewswire.comNorthwest Biotherapeutics Inc (NWBO) Dividend HistoryMay 25, 2024 | nasdaq.comNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of DirectorsMarch 21, 2024 | prnewswire.comSee More Headlines NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed this year? Northwest Biotherapeutics' stock was trading at $0.7010 at the beginning of 2024. Since then, NWBO stock has decreased by 54.5% and is now trading at $0.3189. View the best growth stocks for 2024 here. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) issued its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.02) EPS for the quarter. The biotechnology company had revenue of $0.51 million for the quarter. How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA) and Company Calendar Last Earnings8/09/2024Today9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CUSIPN/A CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,600,000.00 Net Margins-4,479.03% Pretax Margin-4,479.03% Return on EquityN/A Return on Assets-253.74% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual Sales$1.93 million Price / Sales203.31 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-5.32Miscellaneous Outstanding Shares1,230,455,000Free Float1,123,405,000Market Cap$392.39 million OptionableNot Optionable Beta-0.58 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (OTCMKTS:NWBO) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Northwest Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.